Therapeutic approaches to the correction of vasomotor and psychoemotional menopausal symptoms


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Some of the most common symptoms during menopause are vasomotor disorders in the form of hot flashes and night sweats, and psychoemotional disorders that negatively affect the quality of life of women. Due to the ongoing problems of menopausal hormone replacement therapy (MHT), the search of alternative therapies continues. Objective: Study of efficiency of the dietary supplement «Femo-clim» in the correction of vasomotor and psychoemotional menopausal symptoms. Materials and methods. A randomized placebo-controlled study was conducted involving 40 women with climacteric syndrome (CS) of moderate severity. The patients were randomly divided into two groups: group 1 consisting of 20 women with CS of moderate severity received «Femo-clim» 2 tablets 3 times a day for three month. Group 2 consisting of 20 women with CS of moderate severity received placebo with the same regimen. The dynamics of the symptoms of climacteric syndrome was monitored according to Greene Climacteric Scale (GCS) and Hospital Anxiety and Depression Scale (HADS). The final result was assessed after 3 months of therapy (on the 90th day). Results. At the end of the treatment, a statistically significant decrease in the severity of climacteric syndrome was shown in the group administered with «Femo-clim» where the indicator of disease severity was 9.4±1.7 versus baseline 17.3±1.25 (p<0.001) and compared with endpoints in the placebo group. In the group «Femo-clim» the decrease in the severity of vasomotor disorders (hot flashes and night sweats) was 71.8 % (p<0.001); the decrease in the severity of psychoemotional disorders - 50.8 % (p<0.01). Conclusions: Therapy with «Femo-clim» is an effective remedy for the correction of vasomotor and psychoemotional disorders in menopausal women. «Femo-clim» is an effective alternative remedy for women with contraindications to MHT.

全文:

受限制的访问

作者简介

E. Petrova

Penza State University

Email: petrovaelena2010@yandex.ru
Candidate of Medical Sciences, Associate Professor

D. Chizh

Penza State University

Email: petrovaelena2010@yandex.ru

N. Herzog

Department Clinical Hospital Penza Station Open JSC «Russian Railroads»

Email: petrovaelena2010@yandex.ru
Penza

I. Metalnikova

Department Clinical Hospital Penza Station Open JSC «Russian Railroads»

Email: petrovaelena2010@yandex.ru
Penza

E. Panina

Penza State University

Email: petrovaelena2010@yandex.ru
Candidate of Medical Sciences; Professor

V. Strukov

Penza Institute for Advanced Training of Physicians - Branch of Russian Medical Academy of Continuing Professional Education Ministry of Health

Email: petrovaelena2010@yandex.ru
MD

M. Skorodelova

Penza State University

Email: petrovaelena2010@yandex.ru

D. Elistratov

OOO «Parafarm»

Email: petrovaelena2010@yandex.ru
Penza

参考

  1. Менопаузальная гормональная терапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации (протокол лечения). М.: ФГБУ НЦГАиП, 2015; 49 с.
  2. Дворянский С.А., Емельянова Д.И., Яговкина Н.В. Климактерический синдром: современное состояние вопроса (обзор литературы). Вятский мед. вестн. 2017; 1 (53): 7-15.
  3. Бохан Н.А., Лукьянова Е.В., Симуткин Г.Г. Депрессивные расстройства у женщин в климактерическом возрасте (обзор зарубежной литературы за 2012-2016 гг.). Бюллетень сибирской медицины. 2018; 17 (2): 100-13. doi: 10.20538/1682-0363-2018-2-100-113
  4. Эбзиева З.Х. Дифференцированный подход к ведению женщин в постменопаузе с нарушением сна. Дисс.. канд. мед. наук. М., 2020; 114 с.
  5. Прилепская В.Н. Климактерический синдром: инновации в менопаузальной терапии. РМЖ. 2017; 25 (2): 105-8.
  6. Gold E., Colvin A., Avis N. et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the men-opausal transition: Study of Women’s Health Across the Nation. Am JPublic Health. 2006; 96 (7): 1226-35. doi: 10.2105/AJPH.2005.066936
  7. Williams R., Kalilani L., Di Benedetti D. et al. Healthcare seeking and treatment for menopausal symptoms in the United States. Maturitas. 2007; 58 (4): 348-58. doi: 10.1016/j.maturitas.2007.09.006
  8. Assaf A., Bushmakin A., Joyce N. et al. The relative burden of menopausal and postmenopausal symptoms versus other major conditions: a retrospective analysis of the Medical Expenditure Panel Survey data. Am Health Drug Benefits. 2017; 10 (6): 311-21.
  9. Sarrel P., Portman D., Lefebvre P. et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2015; 22 (3): 260-6. doi: 10.1097/GME.0000000000000320
  10. Lucas R., Ganio M., Pearson J. et al. Brain blood flow and cardiovascular responses to hot flashes in postmenopausal women. Menopause. 2013; 20 (3): 299-304. doi: 10.1097/GME.0b013e31826e45f0
  11. Pines A. Vasomotor symptoms and cardiovascular disease risk. Climacteric. 2011; 14: 535-6. doi: 10.3109/13697137.2011.599058
  12. Skrapits K., Borsay B., Herczeg L. et al. Neuropeptide co-expression in hypothalamic kisspeptin neurons of laboratory animals and the human. Front Neurosci. 2015; 9: 29. doi: 10.3389/fnins.2015.00029
  13. Fergani C., Navarro V. Expanding the role of tachykinins in the neuroendocrine control of reproduction. Reproduction. 2016; 153 (1): 1-14. doi: 10.1530/REP-16-0378
  14. Rance N., Dacks P., Mittelman-Smith M. et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013; 34 (3): 211-27. doi: 10.1016/j.yfrne.2013.07.003
  15. Padilla S., Johnson C., Barker F. et al. A neural circuit underlying the generation of hot flushes. Cell Rep. 2018; 24 (2): 271-7. doi: 10.1016/j.celrep.2018.06.037
  16. Skorupskaite K., George J., Anderson R. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014; 20 (4): 485500. doi: 10.1093/humupd/dmu009
  17. Ruka K., Burger L., Moenter S. Both estrogen and androgen modify the response to activation of neurokinin-3 and k-opioid receptors in arcuate kisspeptin neurons from male mice. Endocrinology. 2016; 157 (2): 752-63. doi: 10.1210/en.2015-1688
  18. Rometo A., Krajewski S., Voytko M. et al. Hypertrophy and increased kisspeptin gene expression in the hypothalamic in- fundibular nucleus of postmenopausal women and ovariectomized monkeys. J Clin Endocrinol Metab. 2007; 92 (7): 2744-50. doi: 10.1210/jc.2007-0553
  19. Gomez-Santos C., Saura C.B., Lucas J.A.R. et al. Menopause status is associated with circadian- and sleep-related alterations. Menopause. 2016; 23: 682. doi: 10.1097/GME.0000000000000612
  20. Радзинский В.Е., Ордиянц И.М. Лечение климактерических расстройств в менопаузе. РМЖ. 2018; 5 (I): 37-40.
  21. Sturdee D.W., Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13 (6): 509-22. doi: 10.3109/13697137.2010.522875
  22. Сметник В.П. Заместительная гормонотерапия в климактерии. Status Praesens. Гинекология. Акушерство. Бесплодный брак. 2011.2 (5): 50-4.
  23. Grant M.D., Marbella A., Amy M.S., et al. Menopausal Symptoms: Comparative Effectiveness of Therapies. Comparative Effectiveness Review. 2015; 147: 1-106.
  24. Pinkerton J., Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause. 2015; 22 (9): 926-36. doi: 10.1097/GME.0000000000000420
  25. Tao M., Teng Y., Shao H. et al. Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis. PLoS One. 2011; 6 (9): e24661. doi: 10.1371/journal.pone.0024661
  26. Торшин И.Ю., Громова О.А., Лиманова О.А. Быстрый эффект клималанина (ß-аланина) при приливах: сравнительное исследование взаимодействий бета-аланина, таурина и глицина с глициновыми рецепторами. Гинекология. 2012; 2: 25-9.
  27. Петрова Е.В., Калистратов В.Б., Полубояринов П., и др. Применяемый при климаксе препарат Фемо-Клим - лучшее негормональное решение гормональных проблем. Врач. 2019; 30 (1): 46-8. https://doi.org/10.29296/25877305-2019-01-08
  28. Джоунс О., Струков В.И. Коморбидный остеопороз: проблемы и новые возможности терапии (Ч. 2). Врач. 2017; 11: 25-8.
  29. Потупчик Т.В. Возможности применения препарата Фемо-Клим в климактерическом периоде. Врач. 2019; 30 (8): 80-5 https://doi.org/10.29296/25877305-2019-08-17
  30. Gartoulla P., Han M.M. Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis. Maturitas. 2014; 79 (1): 58-64 doi: 10.1016/j.maturitas.2014.06.018
  31. Cegiela U., Folwarczna J., Pytlik M. et al. Effects of Extracts from Trifolium medium L. and Trifolium pratense L. on Development of Estrogen Deficiency-Induced Osteoporosis in Rats. Evid Based Complement Alternat Med. 2012; 12: 921684. doi: 10.1155/2012/921684
  32. Hwang J., Wang J., Morazzoni P. et al. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med. 2003; 34: 1271-82. doi: 10.1016/s0891-5849(03)00104-7
  33. Milan M.T., Dotlic J., Maricic S. Influence of red clover-derived isoflavones on serum lipid profile in postmenopausal women. J Obstet Gynaecol Res. 2009; 35 (6): 1091-5. doi: 10.1111/j.1447-0756.2009.001059.x
  34. Campbell M.J., Woodside J.V., Honour J.W. et al. Effect of red clover-derived isoflavone supplementation on insulin-like growth factor, lipid and antioxidant status in healthy female volunteers: a pilot study. Eur J Clin Nutr. 2004; 58: 173-9. doi: 10.1038/sj.ejcn.1601764
  35. Плаксина Н.Д., Симоновская Х.Ю. Возможности негормональной коррекции вазомоторных пароксизмов в постменопаузе. Status Praesens. Гинекология. Акушерство. Бесплодный брак. 2014; 19: 60-5.

补充文件

附件文件
动作
1. JATS XML
##common.cookie##